Clinical Trial Detail

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Complete title: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Research Study Number	20151174
Principal Investigator	Andrei Shustov, MD
Phase	I/II

Look up trial at NIH

Research Study Description

This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number	20151174
Contact	Seattle Cancer Care Alliance Intake Office
Telephone	800-804-8824 / 206-606-1024

Keywords: Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Solid Tumors; Immunoproliferative Disorders; Immune System Diseases; Lymphatic Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019